<DOC>
	<DOCNO>NCT00010426</DOCNO>
	<brief_summary>OBJECTIVES : I . Determine proportion patient cystinosis experience serious adverse effect treat new formulation cysteamine hydrochloride corneal cystine accumulation . II . Determine proportion patient reduction corneal crystal density 1.00 unit treat regimen .</brief_summary>
	<brief_title>Randomized Study New Formulation Ophthalmic Cysteamine Hydrochloride Corneal Cystine Accumulation Patients With Cystinosis</brief_title>
	<detailed_description>PROTOCOL OUTLINE : This randomize , multicenter study Patients randomize receive current formulation cysteamine hydrochloride drop one eye new formulation cysteamine hydrochloride drop eye . Patients receive two formulation cysteamine hydrochloride assign eye every hour waking hour daily 6 month ( safety study ) 1 year ( efficacy study ) .</detailed_description>
	<mesh_term>Cystinosis</mesh_term>
	<mesh_term>Cysteamine</mesh_term>
	<criteria>PROTOCOL ENTRY CRITERIA : Disease Characteristics Diagnosis cystinosis 2 nmole halfcystine/mg protein leukocytes OR presence corneal crystal consistent cystinosis distribute corneal stroma observe slit lamp biomicroscopy Clinical history consistent cystinosis Safety study : History adherence current eye drop followup schedule protocol # 86El0062 Any crystal density score , include zero , photograph , stable improve past year Efficacy study : Crystal density score least 1.00 photograph Concurrently cysteamine least past 6 month Prior/Concurrent Therapy No prior cysteamine drop ( efficacy study ) Patient Characteristics Age : 1 50 ( safety study ) 2 12 ( efficacy study ) Other : Willingness ability tolerate corneal photograph</criteria>
	<gender>All</gender>
	<minimum_age>1 Year</minimum_age>
	<maximum_age>50 Years</maximum_age>
	<verification_date>April 2001</verification_date>
	<keyword>cystinosis</keyword>
	<keyword>rare disease</keyword>
	<keyword>renal genitourinary disorder</keyword>
</DOC>